Enabling personalized cancer care

A cancer diagnosis is frightening. But often, cancer treatment can be successful, especially in the era of precision therapies. At Oncobit, our aim is to precisely monitor individual cancer markers for an optimal therapy management.

Our Story

Oncobit is a MedTech spin-off from the University of Zurich, advancing precision monitoring for personalized cancer care.

At Oncobit, we are driven by the commitment to improve patient care in the face of cancer’s challenges and uncertainties. Our mission revolves around the precise monitoring of individual cancer markers to achieve optimal therapy management and successful treatment outcomes.

Founded as a MedTech spin-off from the University of Zurich, we specialize in the development of precision monitoring assays tailored for personalized cancer care. Recognizing that cancer remains a leading cause of death worldwide, with nearly 10 million lives lost annually according to the World Health Organization (WHO), we believe that novel tools for cancer monitoring are vital to ensure that patients receive the most effective treatments available.


Conventional cancer monitoring methods, encompassing imaging techniques and the measurement of non-specific blood markers, often fall short in providing the essential information required for optimal therapy management. Imaging procedures, while widely employed, carry the drawbacks of radiation exposure, limited tumor detection, and high costs. These limitations can lead to suboptimal treatment decisions, resulting in unnecessary patient suffering and increased healthcare expenses.

Motivated by the limitations of existing options, a dedicated group of physicians and scientists from the University Hospital Zurich and ETH Zurich joined forces, combining their expertise in cancer, life sciences, and entrepreneurship. Under the leadership of CEO Dr. Claudia Scheckel, a seasoned biomedical researcher with over a decade of experience and a management background, Oncobit aims to enable personalized patient care.